A Systematic Literature Review of the Economic Burden in Multiple Myeloma

Maria Rizzo, BSc, MSc; Yingxing Xu, PharmD, PhD; Sumeet Panjabi, PhD; Ike Ikeheano, BSc, MB BS

• Elavera, London, UK; • Elavera, Lexington, MA, USA; • Onyx Pharmaceuticals, Inc., an Amgen subsidiary, South San Francisco, USA

BACKGROUND

- Multiple myeloma is the 9th most common cancer type in the US, with approximately 74,000 new cases and 13,000 deaths in 2016
- The current standard of care includes chemotherapy, bone-targeted agents, immunomodulatory drugs, and monoclonal antibodies

OBJECTIVE

- To review published evidence on the economic burden and costs associated with multiple myeloma

METHODS

- Study inclusion criteria: systematic reviews, randomised trials, non-randomised trials, retrospective and case-control studies
- Data Abstraction: two independent researchers; discrepancies resolved by a third researcher
- Full-text articles assessed for eligibility: n=5,830

RESULTS

- Search Results: n=5,830
- Records after duplicates removed: n=3,573
- Additional records identified through grey literature: n=5

RESULTS (CONT'D)

- Table 3: Summary of Included Studies Reporting the Economic Burden of MM Progression

OBJECTIVE

- To review published evidence on the economic burden and costs associated with multiple myeloma

METHODS

- Study inclusion criteria: systematic reviews, randomised trials, non-randomised trials, retrospective and case-control studies
- Data Abstraction: two independent researchers; discrepancies resolved by a third researcher
- Full-text articles assessed for eligibility: n=5,830

RESULTS

- Search Results: n=5,830
- Records after duplicates removed: n=3,573
- Additional records identified through grey literature: n=5

RESULTS (CONT'D)

- Table 3: Summary of Included Studies Reporting the Economic Burden of MM Progression

OBJECTIVE

- To review published evidence on the economic burden and costs associated with multiple myeloma

METHODS

- Study inclusion criteria: systematic reviews, randomised trials, non-randomised trials, retrospective and case-control studies
- Data Abstraction: two independent researchers; discrepancies resolved by a third researcher
- Full-text articles assessed for eligibility: n=5,830

RESULTS

- Search Results: n=5,830
- Records after duplicates removed: n=3,573
- Additional records identified through grey literature: n=5

RESULTS (CONT'D)

- Table 3: Summary of Included Studies Reporting the Economic Burden of MM Progression

PREFERENCES

- Recommendations: further research is needed to improve the understanding of the economic burden of multiple myeloma

LIMITATIONS AND GAP ANALYSIS

- Our work identified the following evidence gap:
- Limited data on costs associated with HD and HD-MMA

CONCLUSION

- The economic burden of multiple myeloma is high, with significant costs associated with treatment and management

Presented at the ISPOR 17th Annual European Congress • November 8-13, 2014 • Amsterdam, The Netherlands

Funding provided by Onyx Pharmaceuticals